Use of R-NSAID compounds for anti-HIV treatment

• US 20030027867A1
• Filed: 06/28/2002
• Published: 02/06/2003
• Est. Priority Date: 06/29/2001
• Status: Abandoned Application

• Current Assignee: Myriad Genetics, Inc.
• Original Assignee: Myriad Genetics, Inc.
• Inventors: Zavitz, Kenton
• Application Number:
  US10/186,371
• Publication Number:
  US 20030027867A1
• Time in Patent Office: Days
• US Class Current: 514/569
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/10 Laxatives
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention provides a method for treating a patient with HIV infection. The method includes administering to a patient a composition containing a therapeutically effective amount of a R-NSAID or a pharmaceutically acceptable salt or ester thereof. The composition is substantially free of S-NSAID.

Claims

1. A method for treating HIV infection in a patient, comprising:

administering to the patient a composition comprising a therapeutically effective amount of a R-NSAID, wherein said composition is substantially free of the S-enantiomer of said R-NSAID.

2. The method of claim 1, wherein said R-NSAID is an arylpropionic acid or a pharmaceutically acceptable salt or ester thereof.

3. The method of claim 2, wherein said R-NSAlD is selected from the group consisting of R-flurbiprofen, R-ketoprofen, R-naproxen, R-tiaprofenic acid, R-suprofen, R-carprofen, R-pirprofen, R-indoprofen, and R-benoxaprofen.

4. The method of claim 1, wherein said R-NSAID is R-ketorolac.

5. The method of claim 1, wherein said R-NSAID is R-etodolac.

6. A method for treating HIV infection in a patient, comprising:

administering to the patient a composition comprising a therapeutically effective amount of R-flurbiprofen or a pharmaceutically acceptable salt or ester thereof, wherein said composition is substantially free of S-flurbiprofen or a pharmaceutically acceptable salt or ester thereof.

7. The method of claim 6, wherein the ratio of the R-flurbiprofen or a pharmaceutically acceptable salt or ester thereof to the S-flurbiprofen or a pharmaceutically acceptable salt or ester thereof is at least 90:

10 by weight.

8. The method of claim 6, wherein the ratio of the R-flurbiprofen or a pharmaceutically acceptable salt or ester thereof to the S-flurbiprofen or a pharmaceutically acceptable salt or ester thereof is at least 99:

1 by weight.

9. The method of claim 6, wherein the composition contains from about 0.1 mg to 2000 mg of R-flurbiprofen or a pharmaceutically acceptable salt or ester thereof.

10. The method of claim 6, wherein from about 10 mg to 4000 mg per day of R-flurbiprofen or a pharmaceutically acceptable salt or ester thereof is administered to the patient.

11. The method of claim 6, wherein said composition further comprises one or more other anti-HIV compounds.

12. The method of claim 11, wherein said one or more anti-HIV compounds are selected from the group consisting of Zidovudine, Lamivudine, Stavudine, DMP-266, Ritonavir, Nelfinavir, Abacavir, Indinavir, 141-W94, Delavirdine, Indinavir, and Saquinavir, Tenofovir and T-20.

13. The method of claim 6, wherein said pharmaceutical acceptable salt is an alkali metal salt, alkaline earth salt, or ammonium salt.

14. The method of claim 6, wherein said ester is an alkyl ester of from 1 to 6 carbon atoms.

15. A composition useful for the treatment of HIV infection comprising:

a therapeutically effective amount of R-flurbiprofen or a pharmaceutically acceptable salt or ester thereof; and

an anti-HIV compound selected from the group consisting of HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV integrase inhibitors and HIV fusion inhibitors, wherein said composition is substantially free of S-flurbiprofen or a pharmaceutically acceptable salt or ester thereof.

16. The composition according to claim 15, wherein said anti-HIV compound is selected from the group consisting of Zidovudine, Lamivudine, Stavudine, DMP-266, Ritonavir, Nelfinavir, Abacavir, Indinavir, 141-W94, Delavirdine, Indinavir, and Saquinavir, Tenofovir and T-20.

17. A method for preventing AIDS, comprising:

administering to an individual in need of such prevention a composition comprising a prophylactically effective amount of a R-NSAID, wherein said composition is substantially free of the S-enantiomer of said R-NSAID.

18. The method of claim 17, wherein said R-NSAID is an arylpropionic acid or a pharmaceutically acceptable salt or ester thereof.

19. The method of claim 18, wherein said R-NSAID is R-flurobiprofen or a pharmaceutically acceptable salt or ester thereof.

20. The method of claim 19, wherein the composition further comprises an anti-HIV compound selected from the group consisting of HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV integrase inhibitors and HIV fusion inhibitors.

21. A method for identifying an anti-HIV compound, comprising:

providing a R-NSAID that is an arylpropionic acid selected from the group consisting of R-flurbiprofen, R-ketoprofen, R-naproxen, R-tiaprofenic acid, R-suprofen, R-carprofen, R-pirprofen, R-indoprofen, and R-benoxaprofen;

modifying the R-NSAlD to provide a R-NSAID derivative by (1) altering the position of the propionic acid group, (2) altering the position or type of substituents (other than the propionic acid group) on either of the phenyl rings, or (3) altering the bond connecting the two phenyl rings, or performing any combination of (1), (2) and (3); and

determining the effect of said R-NSAID derivative on HIV propagation.

22. The method of claim 21, wherein said R-NSAID is R-flurbiprofen.